Atomo Diagnostics (AT1) Q3 2026 earnings summary

Executive summary

• Achieved a transformative Q3 with strong momentum in HIV tests and Pascal cassettes, expanding into new products and partners, and focusing on FY 2027 and beyond.

• Expanded product pipeline with advanced HIV, syphilis, and liver function tests, securing key regulatory milestones and an exclusive global license for a novel liver test.

• CLIA waiver for Lumos' FebriDx test in the U.S. validates Pascal platform and opens significant US market pathways.

• Strong sales momentum with over AUD 2 million in orders and expanded global commercial footprint across Australia, US, Europe, Asia, and Africa.

• Completed a $3 million capital raise and maintained a debt-free balance sheet to support operational expansion and supply chain resilience.

Financial highlights

• Q3 FY26 revenue reached $814,000, with year-to-date revenue at approximately $3 million, up 4% year-over-year.

• Cash on hand at quarter-end was AUD 2.6 million, with the company remaining debt-free.

• Customer receipts exceeded AUD 1.6 million; received nearly AUD 200,000 in government grant funding.

• Cash outflows for the quarter totaled AUD 2.6 million, focused on delivery and new product development.

• EBITDA trending toward breakeven as revenue channels grow and product offerings expand.

Outlook and guidance

• Anticipates transformational growth in Pascal revenues following US FDA CLIA waiver for FebriDx, unlocking significant US market potential.

• Expecting significant revenue growth in Q4 and a strong finish to FY 2026, with momentum into FY 2027.

• Plans to leverage existing HIV infrastructure for rapid, capital-efficient market entry of new syphilis and liver function tests.

• EBITDA losses are narrowing, with a trajectory toward break-even as revenue expands.

• No specific net profit timeline, but confident in the path to profitability.